Skip to main content
. 2009 Dec 1;180(11):1131–1142. doi: 10.1164/rccm.200902-0179OC

Figure 3.

Figure 3.

Intratracheal bone marrow–derived mesenchymal stem cell (BM-MSC) administration on Postnatal Day 4 improves survival and exercise capacity. (A) Kaplan-Meier survival curve showing significant improvement in survival of MSC-treated animals as compared with untreated or pulmonary artery smooth muscle cell (PASMC)-treated animals. (B) Exercise capacity assessed according to a predetermined protocol shows that MSC-treated animals run for longer distances as compared with untreated or PASMC-treated animals.